# Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

> **NCT02825628** · PHASE2 · COMPLETED · sponsor: **DexTech Medical AB** · enrollment: 55 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Osteodex

## Key facts

- **NCT ID:** NCT02825628
- **Lead sponsor:** DexTech Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2018-06
- **Final completion:** 2020-06
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825628, "Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02825628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*